Disease modifying drugs in idiopathic sclerosing orbital inflammatory syndrome

References

• McCarthy JM, White VA, Harris G, Simons KB, Kennerdell J, Rootman J. Idiopathic sclerosing inflammation of the orbit: immunohistologic analysis and comparison with retroperitoneal fibrosis. Mod Pathol. 1993;6:581–587.
   PubMed Web of Science ®Google Scholar
• Hsuan JD, Selva D, McNab AA, Sullivan TJ, Saeed P, O’Donnell BA. Idiopathic sclerosing orbital inflammation. Arch Ophthalmol. 2006;124(9):1244–1250. doi:10.1001/archopht.124.9.1244.
   PubMedGoogle Scholar
• Liu CH, Ma L, Ku WJ, Kao LY, Tsai YJ. Bilateral idiopathic sclerosing inflammation of the orbit: report of three cases. Chang Gung Med J. 2004; 27(10):758–765.
   PubMedGoogle Scholar
• Brannan PA. A review of sclerosing idiopathic orbital inflammation. Curr Opin Ophthalmol. 2007;18(5):402–404. doi:10.1097/ICU.0b013e3282bfe85b.
   PubMed Web of Science ®Google Scholar
• Mombaerts I, Bilyk JR, Rose GE, McNab AA, Fay A, Dolman PJ, et al. Consensus on diagnostic criteria of idiopathic orbital inflammation using a modified delphi approach. JAMA Ophthalmol. 2017;135(7):769–776.). doi:10.1001/jamaophthalmol.2017.1581.
   PubMed Web of Science ®Google Scholar
• Quan LD, Thiele GM, Tian J, Wang D. The development of novel therapies for rheumatoid arthritis. Expert Opin Ther Pat. 2008;18(7):723–738. doi:10.1517/13543776.18.7.723.
   PubMed Web of Science ®Google Scholar
• Buer JK. A history of the term ”DMARD”. Inflammopharmacology. 2015;23(4):163–171. doi:10.1007/s10787-015-0232-5.
   PubMed Web of Science ®Google Scholar
• Lie E, Kristensen LE, Forsblad-d’Elia H, Zverkova-Sandström T, Askling J, Jacobsson LT, ARTIS Study Group. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis. 2015;74(6):970–978. doi:10.1136/annrheumdis-2014-206616.
   PubMed Web of Science ®Google Scholar
• FDA. Therapeutic biological products approvals. [Online]. https://wayback.archive-it.org/7993/20170112025945/http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080402.htm. Accessed March 4, 2019.
   Google Scholar
• Ø T, Myhr KM, Bø L. Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol. 2016;23(Suppl 1):18–27. doi:10.1111/ene.12883.
   PubMed Web of Science ®Google Scholar
• Kalia LV, Kalia SK, Lang AE. Disease-modifying strategies for Parkinson’s disease. Mov Disord. 2015;30:1442. doi:10.1002/mds.26354.
   PubMed Web of Science ®Google Scholar
• Moujalled D, White AR. Advances in the development of disease-modifying treatments for amyotrophic lateral sclerosis. CNS Drugs. 2016;30(3):227–243. doi:10.1007/s40263-016-0317-8.
   PubMed Web of Science ®Google Scholar
• Seo P. October 24, 2017. Uptodate: overview of immunosuppressive and conventional (non-biologic) disease-modifying drugs in the rheumatic diseases. [Online]. https://www.uptodate.com/contents/overview-of-immunosuppressive-and-conventional-non-biologic-disease-modifying-drugs-in-the-rheumatic-diseases. Accessed March 3, 2019.
   Google Scholar
• Kapadia MK, Rubin PA. The emerging use of TNF alpha inhibitors in orbital inflammatory disease. Int Ophthalmol Clin. 2006;46(2):165–181. doi:10.1097/00004397-200604620-00014.
   PubMedGoogle Scholar
• Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–646. doi:10.1038/clpt.2011.328.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015 November-December;60(6):575–589. doi:10.1016/j.survophthal.2015.06.004.
   PubMed Web of Science ®Google Scholar
• Garrity JA, Coleman AW, Matteson EL, Eggenberger ER, Waitzman DM. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol. 2004;138(6):925–930. doi:10.1016/j.ajo.2004.06.077.
   PubMed Web of Science ®Google Scholar
• Adams AB, Kazim M, Lehman TJ. Treatment of orbital myositis with adalimumab (Humira). J Rheumatol. 2005;32:1374–1375.
   PubMed Web of Science ®Google Scholar
• Rootman J, McCarthy M, White V, Harris G, Kennerdell J. Idiopathic sclerosing inflammation of the orbit: a distinct clinicopathologic entity. Ophthalmology. 1994;101:570–584. doi:10.1016/S0161-6420(94)31298-X.
   PubMed Web of Science ®Google Scholar
• Pemberton JD, Fay A. Idiopathic sclerosing orbital inflammation: a review of demographics, clinical presentation, imaging, pathology, treatment, and outcome. Ophthalmic Plast Reconstr Surg. 2012;28(1):79–83. doi:10.1097/IOP.0b013e318238ecf7.
   PubMed Web of Science ®Google Scholar
• On AV, Hirschbein MJ, Williams HJ, Karesh JW. CyberKnife radiosurgery and rituximab in the successful management of sclerosing idiopathic orbital inflammatory disease. Ophthalmic Plast Reconstr Surg. 2006;22(5):395–397. doi:10.1097/01.iop.0000231549.24125.7a.
   PubMed Web of Science ®Google Scholar
• Winn BJ, Rootman J. Orbital Sclerosing inflammation and systemic disease. Ophthalmic Plast Reconstr Surg. 2012;28(2):107–118. doi:10.1097/IOP.0b013e31823d2103.
   PubMed Web of Science ®Google Scholar
• Sahlin S, Lignell B, Williams M, Dastmalchi M, Orrego A. Treatment of idiopathic sclerosing inflammation of the orbit (myositis) with infliximab. Acta Ophthalmol. 2009;87(8):906–908. doi:10.1111/j.1755-3768.2008.01320.x.
   PubMed Web of Science ®Google Scholar
• Schafranski MD. Idiopathic orbital inflammatory disease successfully treated with rituximab. Clin Rheumatol. 2009;28(2):225–226. doi:10.1007/s10067-008-1040-8.
   PubMed Web of Science ®Google Scholar
• Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;11(7):356. doi:10.1016/j.ophtha.2009.06.060.
   Web of Science ®Google Scholar
• Eagle K, King A, Fisher C, Souhami R. Cyclophosphamide induced remission in relapsed, progressive idiopathic orbital inflammation (‘Pseudotumour’). Clin Oncol (R Coll Radiol). 1995;7(6):402–404. doi:10.1016/S0936-6555(05)80017-2.
   PubMedGoogle Scholar
• Chen K, Wei Y, Sharp GC, Braley-Mullen H. Decreasing TNF-alpha results in less fibrosis and earlier resolution of granulomatous experimental autoimmune thyroiditis. J Leukoc Biol. 2007;81(1):306–314. doi:10.1189/jlb.0606402.
   PubMed Web of Science ®Google Scholar
• Doctor P, Sultan A, Syed S, Christen W, Bhat P, Foster CS. Infliximab for the treatment of refractory scleritis. Br J Ophthalmol. 2010;94(5):579–583. doi:10.1136/bjo.2008.150961.
   PubMed Web of Science ®Google Scholar
• Bitossi A, Bettiol A, Silvestri E, Di Scala G, Bacherini D, Lopalco G, et al. Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study. Mediators Inflamm. 2019;10:1623847.
   Google Scholar
• Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165–178. doi:10.1136/annrheumdis-2012-202545.
   PubMed Web of Science ®Google Scholar
• Benucci M, Li Gobbi F, Meacci F, Mackay F, Mariette X, Marcelli C. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. Biologics. 2015;17:7–12.
   Google Scholar
• Verma S, Kroeker KI, Fedorak RN. Adalimumab for orbital myositis in a patient with Crohn’s disease who discontinued infliximab: a case report and review of the literature. BMC Gastroenterol. 2013;13:59. doi:10.1186/1471-230X-13-59.
   PubMed Web of Science ®Google Scholar
• Sa HS, Lee JH, Woo KI, Kim YD. IgG4-related disease in idiopathic sclerosing orbital inflammation. Br J Ophthalmol. 2015;99(11):1493–1497. doi:10.1136/bjophthalmol-2014-305528.
   PubMed Web of Science ®Google Scholar
• Levine MR, Kaye L, Mair S, Bates J. Multifocal fibrosclerosis: report of a case of bilateral idiopathic sclerosing pseudotumor and retroperitoneal fibrosis. Arch Ophthalmol. 1993;111(6):841–843. doi:10.1001/archopht.1993.01090060129037.
   PubMedGoogle Scholar
• Suhler EB, Lim LL, Beardsley RM, Giles TR, Pasadhika S, et al. Rituximab therapy for refractory orbital inflammation. Results of a phase 1/2, dose-ranging, randomized clinical trial. JAMA Ophthalmol. 2014;132(5):572–578. doi:10.1001/jamaophthalmol.2013.8179.
   PubMed Web of Science ®Google Scholar